TMDX Stock Analysis: TransMedics | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 2.453m USD | 12M Return: -47.4% | US89377M1099 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 61.7M
Qual. Beats: 0
Rev. Trend: 96.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 7.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
TransMedics Group, Inc. (NASDAQ: TMDX) is a U.S.-based, commercial-stage medical technology company focused on improving outcomes for patients with end-stage organ failure through innovations in organ transplant therapy. Founded in 1998 and headquartered in Andover, Massachusetts, the company went public on NASDAQ in May 2019 and operates in both the United States and international markets.
The companys flagship platform is the Organ Care System (OCS), a portable perfusion, optimization, and monitoring technology designed to maintain donor organs under near-physiologic conditions outside of the human body. The platform includes three primary product lines-OCS LUNG, OCS Heart, and OCS Liver-addressing preservation needs for both donation-after-brain-death (DBD) and donation-after-circulatory-death (DCD) organs used in transplantation procedures.
In addition to its medical device offerings, TransMedics operates a National OCS Program that provides a turnkey solution for outsourced organ retrieval, along with dedicated organ management and logistics services encompassing aviation, ground transportation, and case coordination. This hybrid model blends capital equipment sales with recurring service revenue, distinguishing the company within the broader Health Care Equipment sub-sector of the GICS Health Care classification.
- OCS organ transplant revenue accelerates with new center adoption
- National OCS logistics margins pressured by aviation and transportation costs
- FDA approvals expand OCS addressable transplant market
| Net Income: 151.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 3.45 > 1.0 |
| NWC/Revenue: 82.70% < 20% (prev 94.39%; Δ -11.69% < -1%) |
| CFO/TA 0.10 > 3% & CFO 145.9m > Net Income 151.7m |
| Net Debt (748.8m) to EBITDA (130.2m): 5.75 < 3 |
| Current Ratio: 6.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (40.7m) vs 12m ago 0.37% < -2% |
| Gross Margin: 58.69% > 18% (prev 59.79%; Δ -1.10% > 0.5%) |
| Asset Turnover: 56.77% > 50% (prev 59.66%; Δ -2.89% > 0%) |
| Interest Coverage Ratio: 4.42 > 6 (EBIT TTM 93.8m / Interest Expense TTM 21.2m) |
| A: 0.38 (Total Current Assets 651.1m - Total Current Liabilities 98.3m) / Total Assets 1.46b |
| B: -0.17 (Retained Earnings -256.0m / Total Assets 1.46b) |
| C: 0.08 (EBIT TTM 93.8m / Avg Total Assets 1.18b) |
| D: 0.55 (Book Value of Equity 518.1m / Total Liabilities 946.3m) |
| Altman-Z'' = 3.02 = A |
| DSRI: 0.79 (Receivables 104.1m/104.9m, Revenue 668.5m/531.3m) |
| GMI: 1.02 (GM 59.79% / 58.69%) |
| AQI: 4.69 (AQ_t 0.08 / AQ_t-1 0.02) |
| SGI: 1.26 (Revenue 668.5m / 531.3m) |
| TATA: 0.00 (NI 151.7m - CFO 145.9m) / TA 1.46b) |
| Beneish M = -0.81 (Cap -4..+1) = D |
As of October 28, 2026, the stock is trading at USD 69.73 with a total of 825,728 shares traded. Over the past week, the price has changed by -6.72%, over one month by -15.71%, over three months by -6.13% and over the past year by -47.35%.
Current recommended Stop Loss: 63.50 (which is 8.9% or 1.6 ATR below the current price).
TransMedics has received a consensus analysts rating of 4.15. Therefore, it is recommended to buy TMDX.
- StrongBuy: 6
- Buy: 3
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 98.7 | 41.6% |
P/E Trailing = 18.3264
P/E Forward = 52.356
P/S = 3.6695
P/B = 12.439
P/EG = 0.7452
Revenue TTM = 668.5m USD
EBIT TTM = 93.8m USD
EBITDA TTM = 130.2m USD
Long Term Debt = 494.0m USD (from longTermDebt, last quarter)
Short Term Debt = 23.6m USD (from shortTermDebt, last quarter)
Debt = 1.22b USD (from shortLongTermDebtTotal, last quarter) + Leases 353.7m
Net Debt = 748.8m USD (calculated: Debt 1.22b - CCE 472.7m)
Enterprise Value = 3.20b USD (2.45b + Debt 1.22b - CCE 472.7m)
Interest Coverage Ratio = 4.42 (Ebit TTM 93.8m / Interest Expense TTM 21.2m)
EV/FCF = 40.51x (Enterprise Value 3.20b / FCF TTM 79.0m)
FCF Yield = 2.47% (FCF TTM 79.0m / Enterprise Value 3.20b)
FCF Margin = 11.82% (FCF TTM 79.0m / Revenue TTM 668.5m)
Net Margin = 22.69% (Net Income TTM 151.7m / Revenue TTM 668.5m)
Gross Margin = 58.69% ((Revenue TTM 668.5m - Cost of Revenue TTM 276.1m) / Revenue TTM)
Gross Margin QoQ = 59.59% (prev 58.16%)
Tobins Q-Ratio = 2.19 (Enterprise Value 3.20b / Total Assets 1.46b)
Interest Expense / Debt = 1.74% (Interest Expense 21.2m / Debt 1.22b)
Taxrate = 24.34% (4.72m / 19.4m)
NOPAT = 71.0m (EBIT 93.8m * (1 - 24.34%))
Current Ratio = 6.62 (Total Current Assets 651.1m / Total Current Liabilities 98.3m)
Debt / Equity = 2.36 (Debt 1.22b / totalStockholderEquity, last quarter 518.1m)
Debt / EBITDA = 5.75 (Net Debt 748.8m / EBITDA 130.2m)
Debt / FCF = 9.47 (Net Debt 748.8m / FCF TTM 79.0m)
Total Stockholder Equity = 460.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 12.88% (Net Income 151.7m / Total Assets 1.46b)
RoE = 32.97% (Net Income TTM 151.7m / Total Stockholder Equity 460.1m)
RoCE = 9.83% (EBIT 93.8m / Capital Employed (Equity 460.1m + L.T.Debt 494.0m))
RoIC = 5.23% (NOPAT 71.0m / Invested Capital 1.36b)
WACC = 6.30% (E(2.45b)/V(3.67b) * Re(8.78%) + D(1.22b)/V(3.67b) * Rd(1.74%) * (1-Tc(0.24)))
Discount Rate = 8.78% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 69.25 | Cagr: 7.39%
[DCF] Terminal Value 77.97% ; FCFF base≈54.4m ; Y1≈62.3m ; Y5≈91.7m
[DCF] Fair Price = 18.21 (EV 1.38b - Net Debt 748.8m = Equity 631.5m / Shares 34.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.18 | # QB: 0
Revenue Correlation: 96.68 | Revenue CAGR: 53.53% | SUE: 0.66 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.29 | Chg30d=+2.09% | Revisions=-40% | Analysts=10
EPS current Year (2026-12-31): EPS=1.51 | Chg30d=-0.47% | Revisions=-50% | GrowthEPS=-42.4% | GrowthRev=+22.6%
EPS next Year (2027-12-31): EPS=2.25 | Chg30d=-1.32% | Revisions=-40% | GrowthEPS=+49.0% | GrowthRev=+17.8%
[Analyst] Revisions Ratio: -70% (up=0, down=7)